iRhythm Technologies (IRTC) to Release Earnings on Thursday

iRhythm Technologies (NASDAQ:IRTC) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect iRhythm Technologies to post earnings of ($0.99) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

iRhythm Technologies (NASDAQ:IRTC) last issued its earnings results on Thursday, February 22nd. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.66). iRhythm Technologies had a negative return on equity of 56.38% and a negative net margin of 25.05%. The company had revenue of $132.51 million during the quarter, compared to analyst estimates of $131.14 million. On average, analysts expect iRhythm Technologies to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

iRhythm Technologies Trading Up 0.1 %

Shares of IRTC opened at $116.43 on Thursday. iRhythm Technologies has a 1 year low of $70.24 and a 1 year high of $138.64. The company has a current ratio of 2.15, a quick ratio of 2.02 and a debt-to-equity ratio of 0.17. The stock has a 50 day simple moving average of $111.45 and a 200-day simple moving average of $101.94. The stock has a market cap of $3.62 billion, a PE ratio of -28.75 and a beta of 1.30.

Insider Buying and Selling at iRhythm Technologies

In other iRhythm Technologies news, CEO Quentin S. Blackford sold 24,701 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $121.96, for a total value of $3,012,533.96. Following the transaction, the chief executive officer now directly owns 180,015 shares in the company, valued at approximately $21,954,629.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CTO Mark J. Day sold 1,475 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $121.96, for a total value of $179,891.00. Following the transaction, the chief technology officer now directly owns 64,412 shares in the company, valued at approximately $7,855,687.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Quentin S. Blackford sold 24,701 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $121.96, for a total value of $3,012,533.96. Following the completion of the transaction, the chief executive officer now owns 180,015 shares in the company, valued at $21,954,629.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,052 shares of company stock worth $4,274,942. Insiders own 0.68% of the company’s stock.

Analysts Set New Price Targets

IRTC has been the subject of a number of recent research reports. JPMorgan Chase & Co. dropped their target price on iRhythm Technologies from $142.00 to $133.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Canaccord Genuity Group raised their price target on iRhythm Technologies from $121.00 to $133.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Finally, Needham & Company LLC raised their price target on iRhythm Technologies from $136.00 to $137.00 and gave the company a “buy” rating in a report on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $135.11.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.